Oncopeptides AB Cash Flow-to-Debt Ratio
Oncopeptides AB cash flow-to-debt ratio. Oncopeptides AB (ONCO) has a Cash Flow-to-Debt Ratio of -1.12x as of December 2025, meaning its operating cash flow of Skr-216.49 Million could theoretically repay -1% of its total liabilities (Skr193.73 Million) in one year. See ONCO FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Oncopeptides AB (2014–2025)
Cash flow-to-debt ratio of Oncopeptides AB from 2014 to 2025. Historical debt coverage capacity for Oncopeptides AB across 12 annual periods. Check Oncopeptides AB total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Oncopeptides AB Cash Flow-to-Debt Ratio by Year (2014–2025)
Oncopeptides AB cash flow-to-debt ratio by year from 2014 to 2025. Year-by-year debt coverage analysis for Oncopeptides AB. For the full cash flow conversion analysis, see ONCO cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.15x | Skr-222.88 Million | Skr193.73 Million | ▲ +16.2% |
| 2024 | -1.37x | Skr-260.57 Million | Skr189.91 Million | ▲ +10.8% |
| 2023 | -1.54x | Skr-279.49 Million | Skr181.60 Million | ▲ +66.7% |
| 2022 | -4.62x | Skr-420.51 Million | Skr91.03 Million | ▲ +30.4% |
| 2021 | -6.64x | Skr-1.52 Billion | Skr228.51 Million | ▼ -89.3% |
| 2020 | -3.51x | Skr-1.30 Billion | Skr369.86 Million | ▲ +0.3% |
| 2019 | -3.51x | Skr-690.57 Million | Skr196.47 Million | ▼ -35.5% |
| 2018 | -2.59x | Skr-333.73 Million | Skr128.70 Million | ▲ +41.0% |
| 2017 | -4.39x | Skr-271.50 Million | Skr61.82 Million | ▼ -23.4% |
| 2016 | -3.56x | Skr-104.26 Million | Skr29.30 Million | ▲ +52.8% |
| 2015 | -7.54x | Skr-52.81 Million | Skr7.00 Million | ▼ -32.4% |
| 2014 | -5.70x | Skr-31.44 Million | Skr5.52 Million | — |